Luye Pharma Group Ltd. (SWB:LUP) Filings
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| VOLUNTARY ANNOUNCEMENT APPROVAL OF THE GROUP'S INNOVATIVE DRUG RUOXINLIN IN CHINA FOR THE NEW INDICATION OF GENERALIZED ANXIETY DISORDER | Nov 19, 2026 | Operations update | HKEX |
| VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR THE GROUP'S INNOVATIVE DRUG LY03021 FOR CLINICAL TRIALS IN THE U.S. | Nov 16, 2026 | Other filings | HKEX |
| VOLUNTARY ANNOUNCEMENT RENEWED INCLUSION OF THE GROUP'S INNOVATIVE ANTIDEPRESSANT RUOXINLIN IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST | Nov 15, 2026 | Other filings | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026 | Nov 5, 2026 | Monthly return | HKEX |
| Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026 | Oct 7, 2026 | Monthly return | HKEX |
| Interim Report 2026 | Sep 29, 2026 | Interim report | HKEX |